Featured News

Anokion SA released successful results from their Phase 1 ACeD clinical trial and they will be moving forward with Phase 2 trials later this year.

Celiac Disease Foundation Chief Executive, Marilyn G. Geller, was recently interviewed by The Waiting Room, a patient information website, to highlight the work and accomplishments of the Foundation.

The Celiac Disease Foundation is pleased to announce the establishment of two international celiac disease research prizes to inspire a new generation of researchers whose work in celiac disease will be invaluable.

researchers concluded that patients with celiac disease who are infected with COVID-19 are not at higher risk of hospitalization.

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

9 Meters Biopharma, Inc., a clinical-stage company focused on rare and unmet needs in gastroenterology, announced their collaboration with the Celiac Disease Foundation to support clinical trial enrollment.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Society for the Study of Celiac Disease (SSCD) has released a statement on the COVID-19 vaccination and its safety for celiac disease patients.

Celiac Disease Foundation Young Investigator Award recipient Jocelyn Silvester, MD, publishes “A new diagnostic paradigm for celiac disease.”